ELAN vs. ONC, BNTX, INSM, SMMT, TEVA, GMAB, ASND, RDY, VTRS, and QGEN
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health vs. Its Competitors
BeOne Medicines (NASDAQ:ONC) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
Elanco Animal Health has a net margin of 9.68% compared to BeOne Medicines' net margin of -3.89%. Elanco Animal Health's return on equity of 7.04% beat BeOne Medicines' return on equity.
BeOne Medicines has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Elanco Animal Health had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Elanco Animal Health and 11 mentions for BeOne Medicines. Elanco Animal Health's average media sentiment score of 0.71 beat BeOne Medicines' score of 0.32 indicating that Elanco Animal Health is being referred to more favorably in the news media.
Elanco Animal Health has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
BeOne Medicines currently has a consensus price target of $330.89, suggesting a potential upside of 5.88%. Elanco Animal Health has a consensus price target of $17.33, suggesting a potential downside of 1.09%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe BeOne Medicines is more favorable than Elanco Animal Health.
Summary
Elanco Animal Health beats BeOne Medicines on 12 of the 17 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
This page (NYSE:ELAN) was last updated on 8/20/2025 by MarketBeat.com Staff
MarketBeat All Access